Technology
Health
Biotechnology

Genocea Biosciences

$0.6101
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0578 (-8.65%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell GNCA and other stocks, options, ETFs, and crypto commission-free!

About

Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Read More Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

Employees
61
Headquarters
Cambridge, Massachusetts
Founded
2006
Market Cap
57.95M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
472.39K
High Today
$0.6734
Low Today
$0.5727
Open Price
$0.6734
Volume
257.41K
52 Week High
$1.15
52 Week Low
$0.28

Collections

Technology
Health
Biotechnology
Cancer Prevention
2014 IPO
US
North America

News

Yahoo FinanceMar 13

Will Genocea Biosciences Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Genocea Biosciences, Inc. GNCA. The stock has moved higher by 47% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. We certainly think that this might be the case, particularly if you consider GNCA’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as G...

472
Yahoo FinanceMar 7

Top Ranked Momentum Stocks to Buy for March 7th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 7th: La-Z-Boy Incorporated (LZB): This furniture products and accessories manufacturer has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.3% over the last 60 days. La-Z-Boy Incorporated Price and Consensus Scroll to continue with content Ad La-Z-Boy Incorporated Price and Consensus La-Z-Boy Incorporated price-consensus-chart | La-Z-Bo...

343
Markets InsiderMar 6

Genocea to Present at the Cowen & Company 39th Annual Health Care Conference

CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the Cowen & Company 39th Annual Health Care Conference on Wednesday, March 13th at 11:20 A.M. ET in Boston, Massachusetts. A live webcast of the presentation can be accessed by visiting the "Events and Presentations" tab of the i...

213

Earnings

-$0.59
-$0.41
-$0.23
-$0.05
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.